Treating progressive familial intrahepatic cholestasis
Part of Digestive system clinical trials.
This study tracks treatments and outcomes for people with a confirmed genetic form of PFIC, a rare liver disease. It helps doctors learn which treatments work best for each type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic diagnosis of PFIC type disease (such as FIC1, BSEP, MDR3, or other listed deficiencies).
- You must have genetic testing results available to confirm the diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different genetic liver conditions called PFIC and follows how they progress over time. It also studies whether a procedure called biliary diversion may improve symptoms or long-term outcomes.
This study looks at how genes affect bile flow problems in the liver. If you have a rare genetic condition like PFIC, researchers want to understand your specific type better by comparing your genes to your symptoms.
This study follows patients with PFIC (a rare liver disease affecting bile flow) who are taking or planning to take odevixibat (Bylvay), a medication that helps manage the condition. Researchers will track how well the medication works, any side effects, and long-term health outcomes in Chinese patients.
This study looks for new genes that might cause abnormal liver test results or specific bile duct diseases in adults, when standard testing hasn't found a clear cause. It also uses healthy blood donors as a comparison group.
This study is tracking how well odevixibat (Bylvay) works and how safe it is for people with progressive familial intrahepatic cholestasis (PFIC) in South Korea. It is for patients who are already prescribed this medicine by their doctor, and it monitors their progress over time.
This study looks at the long-term safety and effects of Livmarli (maralixibat) in children with Alagille syndrome or progressive familial intrahepatic cholestasis (PFIC). It may help understand how well the medicine works over time for itching and other symptoms.
Hear when a new Progressive Familial Intrahepatic Cholestasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.